8-Cyclopentyl-1,3-dipropylxanthine (DPCPX, PD-116,948) is a drug which acts as a potent and selectiveantagonist for the adenosineA1receptor. It has high selectivity for A1 over other adenosine receptor subtypes, but as with other xanthine derivatives DPCPX also acts as a phosphodiesterase inhibitor, and is almost as potent as rolipram at inhibiting PDE4. It has been used to study the function of the adenosine A1 receptor in animals, which has been found to be involved in several important functions such as regulation of breathing and activity in various regions of the brain, and DPCPX has also been shown to produce behavioural effects such as increasing the hallucinogen-appropriate responding produced by the 5-HT2A agonist DOI, and the dopamine release induced by MDMA, as well as having interactions with a range of anticonvulsant drugs.
^Coates J, Sheehan MJ, Strong P (May 1994). "1,3-Dipropyl-8-cyclopentyl xanthine (DPCPX): a useful tool for pharmacologists and physiologists?". General Pharmacology25 (3): 387–94. PMID7926579.
^Moro S, Gao ZG, Jacobson KA, Spalluto G (March 2006). "Progress in the pursuit of therapeutic adenosine receptor antagonists". Medicinal Research Reviews26 (2): 131–59. doi:10.1002/med.20048. PMID16380972.
^Vanattou-Saïfoudine N, Gossen A, Harkin A (January 2011). "A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA "Ecstasy"-induced striatal dopamine release". European Journal of Pharmacology650 (1): 220–8. doi:10.1016/j.ejphar.2010.10.012. PMID20951694.
^Chwalczuk K, Rubaj A, Swiader M, Czuczwar SJ (2008). "[Influence of the antagonist of adenosine A1 receptors, 8-cyclopentyl-1 ,3-dipropylxanthine, upon the anticonvulsant activity of antiepileptic drugs in mice]". Przegla̧d Lekarski (in Polish) 65 (11): 759–63. PMID19205356.